GPP
URGN icon

Great Point Partners’s UroGen Pharma URGN Stock Holding History

Great Point Partners’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-187,843
Closed -$2M – 35
2024
Q4 		$2M Sell
187,843
-570,943
-75% -$6.84M 0.94% 26
2024
Q3 		$9.64M Sell
758,786
-2,147,473
-74% -$31.9M 2.84% 16
2024
Q2 		$48.8M Buy
2,906,259
+285,714
+11% +$4.06M 9.34% 1
2024
Q1 		$39.3M Hold
2,620,545
– – 6.13% 3
2023
Q4 		$39.3M Hold
2,620,545
– – 6.7% 3
2023
Q3 		$36.7M Buy
+2,620,545
New +$42.1M 6.69% 1
2023
Q2 		– Sell
-39,222
Closed -$362K – 51
2023
Q1 		$362K Sell
39,222
-520,778
-93% -$4.79M 0.07% 44
2022
Q4 		$4.97M Sell
560,000
-313,424
-36% -$2.97M 0.97% 35
2022
Q3 		$7.27M Hold
873,424
– – 1.75% 21
2022
Q2 		$7.15M Hold
873,424
– – 1.72% 23
2022
Q1 		$7.61M Hold
873,424
– – 1.84% 21
2021
Q4 		$8.31M Buy
873,424
+123,424
+16% +$1.74M 1.85% 24
2021
Q3 		$12.6M Buy
+750,000
New +$11.9M 2.94% 14

Other funds holding URGN

UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Great Point Partners's URGN Position: Q1 2025 in Review

Great Point Partners sold out of UroGen Pharma (URGN) in Q1 2025, closing a stake of 187,843 shares — an estimated $2M sold.

Great Point Partners first reported a position in URGN in Q3 2021 and held it in 13 quarters. The position peaked at $48.8M in Q2 2024. 140 funds tracked by Wall St. Rank hold URGN as of Q1 2025.

  • Great Point Partners reported no remaining UroGen Pharma position as of Q1 2025 after selling out during the quarter.
  • Great Point Partners sold 187,843 UroGen Pharma shares in Q1 2025, an estimated $2M.
  • Great Point Partners first reported a position in UroGen Pharma in Q3 2021 and held it in 13 quarters.
  • Great Point Partners's UroGen Pharma position peaked at $48.8M in Q2 2024.
  • 140 funds tracked by Wall St. Rank held UroGen Pharma as of Q1 2025.

Based on Great Point Partners's 13F filing for Q1 2025, filed 15 May 2025.